Introduction
Light chain deposition disease (LCDD) and crystal-storing histiocytosis (CSH) are uncommon systemic immunoglobulin deposition diseases for which limited molecular information and guidelines for treatment are available. LCDD is caused by an underlying clonal plasma cell dycrasia in which monoclonal immunoglobulin light chains, usually of a k isotype, are deposited in tissues resulting in varying degrees of organ dysfunction. This disorder was originally described by Randall et al. 1 in 1976 in two patients with terminal kidney failure, one with a previous diagnosis of multiple myeloma and the other with idiopathic lobular glomerulonephritis. Pathologic evaluation revealed a granular deposition disease containing antigenic determinants of free light chains that did not bind Congo red, thus distinguishing it from AL (primary systemic) amyloidosis in which light chain deposits form characteristic amyloid fibrils that bind Congo red dye. LCDD is an uncommon disorder, for which treatment experience has been limited; however, conventional chemotherapy with oral melphalan and prednisone, as used in multiple myeloma, has been tried with little evidence of lasting benefit. 2 Recently the use of high, myeloablative doses of melphalan combined with autologous stem cell transplantation (HDM/SCT), as has been used to treat multiple myeloma and systemic AL amyloidosis, has been described for patients with both heavy and light chain deposition diseases. [3] [4] [5] These retrospective series demonstrate feasibility and safety of HDM/ SCT. Moreover, hematologic responses were durable and associated with regression of light chain deposits and improvement in renal function.
In CSH, monoclonal light chain deposits form intracytoplasmic crystalline inclusions. This disorder was first described in 1978 by Terashima et al. 6 and has since been reported in association with both plasma cell and lymphoid disorders. Here, the monoclonal light chain, again usually k isotype, forms crystalline intracellular inclusions within histiocytes. A recent case report described the features of the light chain in detail; this patient was unresponsive to treatment with steroids.
Here, we describe the molecular features of the variant light chains produced in the bone marrow, and our experience with the use of HDM/SCT to treat six patients with non-amyloid light chain deposition diseases (five with LCDD and one with CSH).
Materials and methods

Patient evaluation
LCDD or CSH was demonstrated by biopsy of the kidney, and evidence of an underlying plasma cell dyscrasia was demonstrated by the presence of clonal plasma cells in the bone marrow and/or monoclonal light chains in serum or urine detectable by immunofixation electrophoresis and/or abnormally elevated serum free light chain levels or ratios. All patients were evaluated by a hematologist, a nephrologist, and a cardiologist to determine the extent of organ system involvement by physical exam, blood tests, electrocardiogram, transthoracic echocardiogram (TTE), 24 h urine collection for proteinuria, chest X-ray and pulmonary function tests. Renal involvement was defined as proteinuria and/or abnormal creatinine clearance with a characteristic renal biopsy. Cardiac involvement was suspected if interventricular septal thickness on TTE was 412 mm with normal/high voltage on ECG. Performance status was assessed according to Southwest Oncology Group (SWOG) criteria. Data was collected with the approval of the Institutional Review Board at Boston University Medical Center.
Analysis of clonal light chains
At the time of evaluation, a portion of the bone marrow aspirate specimen was treated with ammonium chloride to lyse red blood cells, which were then washed and pelleted. Total RNA was extracted from 10 7 cells using Trizol (Invitrogen Life Technologies, Carlsbad, CA, USA) and cDNA was synthesized with Superscript II reverse transcriptase (Invitrogen Life Technologies, Carlsbad, CA, USA). The cDNA was amplified by multiplex polymerase chain reaction (PCR) using 5 0 primers specific for the framework 1 (FR1) region of 7 Vl (VlI, VlII/V, VlIII, VlIVa, VlIVb, VlVI) and 4 Vk (VkI/IV, VkII, VkIII) families, along with 3 0 constant region Cl or Ck primers. 8 Each specimen was subjected to multiple independent PCR amplifications, cloning and sequencing in the Boston University School of Medicine Genetics Core Facility. To correct minor sequencing errors introduced by the FR1 primers, additional PCR amplification with the appropriate 5 0 primers for specific VL leader regions were performed. The germ-line donor genes were identified by homology using a database of rearranged immunoglobulin genes, V-BASE (www.mrc-cpe.cam.ac.uk) and the International Immunogenetics Information system, IMGT/V-QUEST (http://imgt.cines.fr) The number of somatic mutations was determined from the beginning of FR1 region to the end of the VL segment, excluding the VJ junction and framework region FR4. To evaluate antigen selective pressure, the frequencies of replacement (R) and silent (S) mutations were compared in the FRs and complementaritydetermining regions (CDR). The probability that an excess or scarcity of observed R mutations in the FR and CDR regions of VL occurred by chance was calculated using a multinominal distribution model (www.cbs.dtu/dk). Potential N-glycosylation sites (Asn-X-Ser/Thr, where X is any amino acid except Pro) were predicted using NetNGlyc. 9 
Eligibility criteria
The eligibility criteria for treatment with HDM/SCT included a tissue diagnosis of either light chain deposition disease or crystal storing histiocytosis, and evidence of an underlying plasma cell dyscrasia. Patients were permitted to have undergone a prior chemotherapy as long as organ function and bone marrow reserves were preserved. Patients on dialysis were not excluded. Patients had to meet these requirements at the time of initial evaluation and before stem cell collection in order to proceed with HDM/SCT. Patients were required to provide written informed consent in accordance with institutional review board approval. Patients received prophylactic antimicrobial therapy with acyclovir, levofloxacin and fluconazole beginning on day þ 1. G-CSF (5 mcg/kg/day) was administered from day þ 1 following stem cell infusion until an ANC 4 500 cells/ml was measured on 2 consecutive days. Prophylactic antibiotics were also discontinued at this time.
Treatment plan
Measurement of treatment response
Patients who completed HDM/SCT were assessed for hematologic and clinical responses at 3, 6 and 12 months, and annually thereafter. Serum-free light chain levels were measured by a nephlometric immunoassay in all patients both before and 14 days after treatment, as well as at each follow-up visit. A complete hematologic response (CR) was defined as a complete disappearance of monoclonal Ig protein in the serum and urine and normalization of the serum-free light chain ratio, combined with a bone marrow biopsy that showed o5% plasma cells without clonal dominance of k or l isotypes. An incomplete response was indicated by persistence of clonal plasma cells in the bone marrow, persistence of a detectable monoclonal protein in the serum or urine by immunofixation electrophoresis, or by persistence of an abnormal serum-free light chain ratio. Creatinine clearance and 24 h urinary protein excretion were measured at each follow-up visit.
Results
LCDD patient characteristics
Between 2003 and 2005, five patients with LCDD were treated at Boston University Medical Center. All patients with LCDD were men with a median age of 44.5 years (range 36-51 years). Three of these five patients had a k gammopathy, and all had biopsy-proven renal involvement as well as either proteinuria or elevated serum creatinine concentration. One of these patients (LCDD-k) also had cardiac involvement evident on endomyocardial biopsy (Figure 1 ). This patient had received a renal allograft 4 years earlier for end stage renal disease. Initiation of chronic dialysis was required 6 months before HDM/ SCT because of progressive allograft failure due to biopsy proven LCDD. Median creatinine clearance among the non-dialysis-dependent patients was 31 ml/min (range 21-149 ml/min). Two patients had received prior chemotherapy; one with prednisone and oral melphalan (total dose of melphalan 32 mg) followed by thalidomide and dexamethasone and the other with a single cycle of high-dose pulse dexamethasone approximately 7 weeks before HDM/SCT (Table 1) . Table 1) . The patient had received prior treatment with high-dose pulse dexamethasone followed by a combination of thalidomide and dexamethasone. Creatinine clearance at initiation of HDM/SCT was 64 ml/min.
CSH patient characteristics
The patient with CSH was a 45-year-old man with an IgG k monoclonal protein evident by serum and urine immunofixation electrophoresis. A kidney biopsy, performed because of creatinine elevation, showed crystalline inclusions in proximal tubular epithelial cells and interstitial histiocytes that stained with antibodies against k light chain. The serum k-free light chain level and k/l-free light chain ratio were elevated, and bone marrow biopsy demonstrated 10-15% k-staining plasma cells (
Light chain sequences
Bone marrow aspirates were available for three of the five patients with LCDD, but not for the patient with CSH, who presented after induction treatment and had polyclonal bone marrow plasma cells at the time of evaluation at Boston University Medical Center. The clonal light chains were amplified by PCR from RNA prepared from these aspirates and their nucleotide sequence was determined, from which the encoded amino-acid sequence was deduced. Two of the deduced LCDD light chain sequences belonged to the k I family, with two different germline donors, L19 and L9 ( Table 2 ). The deduced k I L19 sequence differed from the predicted germline L19 sequence in six amino acids of which one replacement mutation introduced a new hydrophobic amino acid, A84V in FR3. The deduced k I L9 amino-acid sequence differed from the L9 germline gene sequence in 17 amino acids, of which four Endomyoardial biopsy tissue demonstrating non-fibrillar light chains (LC) in the extracellular space between cardiomyocytes, whose nuclei (Nuc) and plasmamembrane (membrane) are indicated (shown here at Â 28 000 magnification). Biopsy was fixed in glutaraldehyde, osmicated and embedded in Eponate-Araldite (Pella) and ultra-thin sections were stained with uranyl acetate and lead citrate. Sections were viewed in Philips 300 electron microscope operating at 60 kV. Images were captured onto Kodak SO-163 film and scanned into Photoshop with minor contrast/brightness enhancement but without any other manipulation. introduced new hydrophobic residues (M4L and F11L in FR1, A34V in CDR1, and A51V in CDR2). An amino-acid mutation of threonine to asparagine at position 20 generated a novel potential N-linked glycosylation site. By analysis of the frequency of R and S mutations, neither of these sequences appeared to have been subjected to antigen selection. The third LCDD sequence encoded a light chain in the l III family, with germline donor 2a2. This light chain differed from the sequence predicted by the germline gene in 26 amino acids, of which only two were new hydrophobic residues (M47I and S93L). In this sequence, we found statistically more R mutations in the CDRs (P ¼ 0.00004) and fewer in the FRs (P ¼ 0.0007), consistent with the mutations having been generated through a process of antigen selection. No new potential N-linked glycosylation sites were created in this sequence. This highly mutated light chain also coded for 10 aminoacid substitutions in the constant region, and a three amino-acid insertion of Pro-Gly-His, after position 140. 
HDM/SCT treatment
Hematologic and clinical responses
The median follow-up of treated patients has been 12 months (range 4-29 months), and all are alive and well. Median survival cannot be calculated, as all patients are alive. A complete hematologic response was achieved in five of the six patients (83%). All patients had normalization of their serum-free light chain assays after HDM/ SCT ( Table 1) . The median percent reduction in proteinuria following treatment was 75.3% (range 38.7-89.3) compared to pretreatment levels (Table 1) . One patient with documented cardiac involvement experienced a decrease in intervetricular septal thickness from 18 to 13 mm, 2 years after HDM/SCT, with preservation of the left ventricular ejection fraction. This patient with LCDD, who was dialysis-dependent at the time of treatment, has had a durable hematologic CR over 29 months of follow-up and is now awaiting kidney transplant.
Treatment-related complications
There were no treatment related deaths. However, as expected, all patients experienced grade 4 neutropenia and thrombocytopenia. Four patients also developed febrile neutropenia leading to hospitalization and treatment with broad-spectrum intravenous antibiotics. No positive cultures (blood, urine, sputum and stool) were documented in any of these cases. The median duration of hospital stay was 10.5 days (range 5-12), and one patient required admission to the intensive care unit after developing encephalopathy (the only unexpected grade 4 toxicity), which was believed to be due to intravenous acyclovir, given concomitantly with imipenem. The median duration of intravenous antibiotic treatment was 5.5 days (range 3-11 days), as was the median number of days with an ANC o500 (range 4-6 days). The median day of neutrophil and platelet engraftment was at day 10 and 13, respectively, following stem cell infusion. There were no unexpected grade 4 toxicities related to HDM/SCT per se (Table 3) .
Discussion
We have analyzed the clinical and genetic features of six patients with variant plasma cell disorders, LCDD and CSH, and documented their responsiveness to aggressive treatment with HDM/SCT. As others have reported, these disorders most often are associated with production of k monoclonal light chains, although two of our patients had LCDD due to a l light chain. All of our patients had involvement of the kidney, the organ most often affected in LCDD 10 and previously documented to be affected in CSH. 11 Moreover, in one patient, we had biopsy-proven evidence of cardiac involvement. Cardiac and other major organ involvement should be considered in the assessment of these patients.
The deduced light chain sequences in these cases had some unusual features, including usage of k germline donor genes rarely employed in the normal repertoire 12 and a high rate of somatic mutation. One report on six k LCDD sequences suggested that the acquisition of hydrophobic residues is an important determinant of pathogenicity, 13 and we did see new hydrophobic residues in all of our sequences, although only one substitution was the same as those previously reported (the M4L mutation in the second k sequence). Another report has suggested, based on a single k IV LCDD light chain sequence, that acquisition of N-linked glycosylation might be important for promoting light chain aggregation. 14 We found a new N-linked glycosylation site in only one of our three sequences. Thus, it appears not to be a required modification; our data supports the hypothesis that hydrophobic residues are important. 13 We have also confirmed previous reports of the safety and efficacy of treatment with HDM/SCT for patients with LCDD 3, 4 and for the first time, demonstrated that this can also be the case for patients with CSH. This is consistent with the proven benefits of HDM/SCT for patients with multiple myeloma and the efficacy that we and others have reported for AL amyloidosis. [15] [16] [17] Hematologic responses were followed by improvement in renal function. This is consistent with previous reports, 3, 4 including the description of reversal of dialysis-dependence following HDM/ SCT in one patient. 4 The toxicity of treatment was acceptable and the responses appear to be durable. Thus, we recommend consideration of HDM/SCT for suitable patients with these variant plasma cell disorders.
